GlassScriptPhysician profile
Elisa Gerdes
NPI 1144450339
$6,384.62
in general payments reported to CMS, 2019-2025
46 companies · $1,822 in 2025
The $1,822 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,114 · 2022: $1,043 · 2023: $1,021 · 2024: $1,384 · 2025: $1,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,227.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.44 | 2021-2025 | |
| Pfizer INC. | $697.88 | 2021-2025 | |
| Lilly USA, LLC | $575.49 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.23 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $435.75 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Inspire Medical Systems, INC. | $337.37 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $294.78 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $285.32 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $282.90 | 2021-2025 | |
| Glaxosmithkline, LLC. | $241.50 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $219.49 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $187.61 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $139.99 | 2021-2024 | Otezla, Repatha |
| Corcept Therapeutics | $135.23 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $111.67 | 2024-2025 | Auvelity |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $105.20 | 2022-2025 | Freestyle Libre, Proclaim, Afinion 2 |
| Corium, LLC | $90.45 | 2023-2024 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.21 | 2022-2025 | Xifaxan, Trulance |
| Eisai INC. | $68.86 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $65.36 | 2021-2023 | Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $60.60 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $55.13 | 2024-2025 | Rexulti |
| Dynavax Technologies Corporation | $51.40 | 2024-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $47.75 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $47.26 | 2021-2025 | Gardasil 9, Capvaxive, Belsomra |
| Novartis Pharmaceuticals Corporation | $44.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.66 | 2021-2022 | |
| Amarin Pharma, INC. | $43.28 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $38.47 | 2021 | |
| Lundbeck LLC | $36.23 | 2025 | Vyepti, Rexulti |
| Exact Sciences Corporation | $32.27 | 2023-2025 | Cologuard Collection Kit |
| Tolmar, INC. | $29.62 | 2023-2025 | Jatenzo |
| Clarus Therapeutics INC. | $28.39 | 2021 | |
| Stryker Corporation | $28.33 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Olympus America INC. | $25.57 | 2023 | Spiration Valve System |
| Tris Pharma INC | $24.96 | 2023 | Quillichew Er, Dyanavel Xr, Quillivant |
| Antares Pharma, INC. | $23.67 | 2021-2022 | |
| Seqirus USA INC | $21.51 | 2025 | Fluad, Flucelvax |
| Janssen Pharmaceuticals, INC | $18.58 | 2021 | |
| Globus Medical, INC. | $18.07 | 2025 | Senza |
| Sanofi Pasteur INC. | $17.88 | 2025 | |
| Medtronic, INC. | $15.42 | 2025 | Inceptiv |
| Depuy Synthes Sales INC. | $13.67 | 2023 | Monovisc |
| Ironshore Pharmaceuticals INC. | $13.46 | 2024 | |
| Xeris Pharmaceuticals, INC. | $12.83 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisa Gerdes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.